The effects of bicalutamide on reducing ovarian cancer cell proliferation are less significant after treatment with chemotherapeutic due to reduced levels of AR [49]; therefore, the use of anti-androgen should be considered based on expression of AR and may be more impactful prior to other chemotherapy or as cancer prevention. The gene discussed is AR; the disease is ovarian cancer.